MA45690A - Anticorps anti-tgfb, méthodes et utilisations - Google Patents

Anticorps anti-tgfb, méthodes et utilisations

Info

Publication number
MA45690A
MA45690A MA045690A MA45690A MA45690A MA 45690 A MA45690 A MA 45690A MA 045690 A MA045690 A MA 045690A MA 45690 A MA45690 A MA 45690A MA 45690 A MA45690 A MA 45690A
Authority
MA
Morocco
Prior art keywords
methods
tgfb antibodies
tgfb
antibodies
Prior art date
Application number
MA045690A
Other languages
English (en)
Inventor
Gregory J Carven
Thomas Schurpf
Katherine Turner
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MA45690A publication Critical patent/MA45690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045690A 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations MA45690A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05

Publications (1)

Publication Number Publication Date
MA45690A true MA45690A (fr) 2019-05-22

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045690A MA45690A (fr) 2016-07-14 2017-07-14 Anticorps anti-tgfb, méthodes et utilisations

Country Status (13)

Country Link
US (2) US20190292254A1 (fr)
EP (1) EP3484499A4 (fr)
JP (2) JP7128801B2 (fr)
KR (1) KR102577551B1 (fr)
CN (1) CN110049773A (fr)
AU (1) AU2017294772B2 (fr)
BR (1) BR112019000621A2 (fr)
CA (1) CA3030862A1 (fr)
IL (1) IL264161A (fr)
MA (1) MA45690A (fr)
MX (1) MX2019000514A (fr)
SG (1) SG11201900200XA (fr)
WO (1) WO2018013939A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102362609B1 (ko) 2013-08-01 2022-02-11 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
US11643459B2 (en) 2016-03-11 2023-05-09 Scholar Rock, Inc. TGFβ1-binding immunoglobulins and use thereof
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
WO2019075090A1 (fr) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
TW202019957A (zh) * 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
DK3677278T3 (da) 2018-07-11 2022-01-10 Scholar Rock Inc Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf
EP3863722A2 (fr) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Variants d'anticorps anti-lap et leurs utilisations
CA3128042A1 (fr) 2019-01-30 2020-08-06 Scholar Rock, Inc. Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations
CN114630679A (zh) * 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
WO2022204581A2 (fr) 2021-03-26 2022-09-29 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation
EP4348260A2 (fr) 2021-06-03 2024-04-10 Scholar Rock, Inc. Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
WO2023288277A1 (fr) 2021-07-14 2023-01-19 Scholar Rock, Inc. Inhibiteurs spécifiques du complexe ltbp de tgfb1 et leurs utilisations
CA3230246A1 (fr) * 2021-09-30 2023-04-06 Wenxin Xu Anticorps bispecifique et son application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085678B (zh) * 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
CA2615983A1 (fr) * 2005-07-21 2007-02-01 Abbott Laboratories Expression multigenique comprenant des constructions sorf et methodes faisant appel a des polyproteines, a des pro-proteines, et a une proteolysis
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN103003424B (zh) * 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
NZ631405A (en) * 2012-10-02 2017-01-27 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
LT2981822T (lt) * 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
KR102362609B1 (ko) * 2013-08-01 2022-02-11 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
EP3139957A4 (fr) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions et procédés de modulation de facteur de croissance
US11597778B2 (en) * 2015-04-07 2023-03-07 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to ADAMTS13 and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體

Also Published As

Publication number Publication date
CN110049773A (zh) 2019-07-23
AU2017294772B2 (en) 2024-05-02
US20210277100A1 (en) 2021-09-09
CA3030862A1 (fr) 2018-01-18
JP2022153406A (ja) 2022-10-12
US20190292254A1 (en) 2019-09-26
JP2019524094A (ja) 2019-09-05
MX2019000514A (es) 2019-07-12
AU2017294772A1 (en) 2019-01-31
BR112019000621A2 (pt) 2019-04-24
SG11201900200XA (en) 2019-02-27
JP7128801B2 (ja) 2022-08-31
EP3484499A1 (fr) 2019-05-22
KR102577551B1 (ko) 2023-09-11
EP3484499A4 (fr) 2020-05-13
WO2018013939A1 (fr) 2018-01-18
KR20190034560A (ko) 2019-04-02
IL264161A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA47268A (fr) Anticorps anti-gpc3
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA43814A (fr) Anticorps anti-gitr, méthodes et utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA47472A (fr) Anticorps
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
MA43567A (fr) Anticorps pacap et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA50352A (fr) Anticorps multispécifiques
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder